Skip to main content Skip to navigation Skip to search

Heading

For a challenger brand to keep moving through the decades, we must act smart. In ever-changing times where traditional

Press releases

Nov 15, 2021

Hansa Biopharma to initiate Phase 3 study of imlifidase to treat anti-Glomerular Basement Membrane (anti-GBM) disease after successful pre-IND meeting with U.S. FDA

Nov 12, 2021

Hansa Biopharma Nomination Committee formed

Nov 08, 2021

Hansa Biopharma announces it has confidentially submitted a draft registration statement on Form F-1 to the U.S. SEC relating to a potential U.S. IPO